NCT00086489View on ClinicalTrials.gov

CP-675,206 In Patients With Advanced Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

118

Participants

Timeline

Start Date

August 31, 2003

Primary Completion Date

May 31, 2007

Study Completion Date

May 31, 2009

Conditions
Malignant Melanoma
Interventions
DRUG

CP-675,206

pts treated at 10 mg/kg dose level on a monthly regimen

DRUG

CP-675,206

pts treated at 15 mg/kg dose level on a quarterly regimen

Trial Locations (9)

15232

Research Site, Pittsburgh

33612

Research Site, Tampa

37232

Research Site, Nashville

77030

Research Site, Houston

90095

Research Site, Los Angeles

60637-1460

Research Site, Chicago

48109-0008

Research Site, Ann Arbor

48109-0843

Research Site, Ann Arbor

15232-1305

Research Site, Pittsburgh

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY